Search | Clinical Trials Finder

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: FlexTouch®, FlexPen®; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 65
States / cities: Burlingame, California • Concord, California • Encino, California + 59 more

Conditions: Type 2 Diabetes
Interventions: Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Faster Insulin Aspart (Fiasp®); Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glulisine, Insulin Glargine, Premixed Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Diabetes Type 2
Interventions: Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin); Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 80
States / cities: Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: MYL-1601D Product, FlexPen NovoLog®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 158
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Burlingame, California • Escondido, California • Huntington Beach, California + 50 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 64
States / cities: Concord, California • Fresno, California • Fullerton, California + 56 more

Conditions: Type1 Diabetes Mellitus
Interventions: Aspart; Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart, insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Tucson, Arizona • Concord, California • Encino, California + 49 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Encino, California • Fresno, California • Roseville, California + 25 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: biphasic insulin aspart 30; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Phoenix, Arizona • La Jolla, California • DeLand, Florida + 11 more

Conditions: Type 2 Diabetes
Interventions: Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 29
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 22 more

Conditions: Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions: Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 35 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions: insulin aspart, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin human, insulin lispro, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: FlexPen®, vial and syringe; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir]); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 37
States / cities: Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

Insulin Glargine "All to Target" Trial

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Mylan Insulin Aspart Study

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Linagliptin Inpatient Trial

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes